vimarsana.com

பிரமல் பார்மா லிமிடெட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

UBS Expects Record IPO Year for India Despite Covid-19 Crisis

(Bloomberg) India’s sharp surge in Covid-19 cases will not prevent the country’s markets from setting a record for initial public offerings in 2021, as a cohort of technology companies make their much-anticipated debuts later in the year, according to UBS Group AG. Last year companies amassed $4.6 billion from IPOs, according to data compiled by Bloomberg, and Anuj Kapoor, head of investment banking at UBS India, believes the figure will be easily eclipsed. “I would say we will surpass twice the money we raised in 2020 through IPOs,” Kapoor said. Before the arrival of the coronavirus pandemic’s second wave, India’s markets were full of optimism. So far in 2021, IPOs in India have raised nearly $3 billion, the best start to the year since 2018, the data show. The activity was aided by ample liquidity, with foreign investors as well as retail stock-pickers looking for new ideas to invest in, Kapoor said. Read More: SPACs Look to India for Next Wave of Targets, Nomura Says T

Piramal Enterprises: Hidden Value?

 2 Last year, a decade after Piramal Enterprises Ltd (PEL), erstwhile Piramal Healthcare, sold its domestic formulation business to Abbott Laboratories for US$3.8 billion (probably the biggest pharma deal in India), it sealed another deal in its pharma business. In June 2020, it announced the stake sale of 20% equity in Piramal Pharma Ltd (PPL), the wholly-owned subsidiary of Piramal. Premium Content

Broker s call: Piramal Enterprises (Buy) - The Hindu BusinessLine

Broker s call: Piramal Enterprises (Buy) | Updated on CMP: ₹1744.50 Piramal Enterprises’ (PEL) wholly owned pharma subsidiary Piramal Pharma Ltd (PPL) has announced the acquisition of Hemmo Pharma for an upfront cash consideration of ₹775 crore and additional milestone linked payments. PPL believes that Hemmo’s forte in peptide API manufacturing will not only complement the existing contract development and manufacturing organisation (CDMO) business but also provide additional growth opportunity as well as provide vertical integration led benefits. In our assumption, the deal is valued at 7 times of FY21 sales and 20 times of FY21 EV/EBITDA. We expect Hemmo to grow its revenue at a CAGR of 30 per cent over FY21-FY23. We remain positive on PPL’s unique positioning in the pharma business with its CDMO services and critical care products.

Piramal Enterprises share rises 3% on acquisition of Hemmo Pharmaceuticals

Piramal Enterprises share rises 3% on acquisition of Hemmo Pharmaceuticals Piramal Enterprises share price gained as much as 3.28 per cent to hit a high of Rs 1,809.55 on the BSE BusinessToday.In | April 1, 2021 | Updated 11:11 IST Piramal Enterprises share gains over 3% Shares of Piramal Enterprises surged over 3 per cent in opening trade on Thursday after the company announced the acquisition of Hemmo Pharmaceuticals Private Limited by Piramal Pharma Limited, subsidiary of the company. Boosted by the development, Piramal Enterprises share price gained as much as 3.28 per cent to hit a high of Rs 1,809.55 on the BSE. The stock opened higher at Rs 1,799 against previous close price of Rs 1,752. The market cap of the diversified global business conglomerate rose to Rs 40,360.09 crore. On the volume front, 18,000 shares have changed hands over the counter as compared to two-week average volume of 67,000 shares.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.